

**Table A, web appendix. Concomitant Medications at baseline and on follow up in the study group as a whole and in patients with Complete, Partial or No Remission considered separately**

	Baseline				Follow-up			
	Overall	CR	PR	NR	Overall	CR	PR	NR
	(n= 100)	(n=27)	(n= 38)	(n=35)	(n= 100)	(n=27)	(n= 38)	(n=35)
Vitamin D	19 (19.0)	2 (7.4)	6 (15.9)	11 (31.4)	22 (22.0)	4 (14.8)	5 (13.2)	13 (37.1)
<b>Antithrombotic agents</b>								
Antiplatelet agents	33 (33.0)	8 (29.6)	16 (42.1)	9 (25.7)	46 (46.0)	11 (40.7)	16 (42.1)	19 (54.3)
Anticoagulants	4 (4.0)	0	3 (7.9)	1 (2.9)	6 (6.0)	1 (3.7)	4 (10.5)	1 (2.9)
<b>Antihypertensive agents</b>								
Diuretics	67 (67.0)	20 (74.1)	23 (60.5)	24 (68.6)	63 (63.0)	19 (70.4)	20 (52.6)	24 (68.6)
Beta blockers	13 (13.0)	2 (7.4)	5 (13.2)	6 (17.1)	14 (14.0)	2 (7.4)	8 (21.1)	4 (11.4)
Calcium channel blockers	11 (11.0)	3 (11.1)	4 (10.5)	4 (11.4)	6 (6.0)	3 (11.1)	2 (5.3)	1 (2.9)
ACE inhibitors/ARBs	94 (94.0)	26 (96.3)	34 (89.5)	34 (97.1)	84 (84.0)	24 (88.9)	30 (78.9)	30 (85.7)
Other	3 (3.0)	1 (3.7)	2 (5.3)	0	5 (5.0)	0	3 (7.9)	2 (5.7)
<b>Lipid lowering agents</b>								
Statins	74 (74.0)	20 (74.1)	26 (68.4)	28 (80.0)	64 (64.0)	16 (59.3)	23 (60.5)	25 (71.4)
Other	8 (8.0)	3 (11.1)	2 (5.3)	3 (8.6)	7 (7.0)	3 (11.1)	2 (5.3)	2 (5.7)

Data are expressed as n (%).


Abbreviations: CR: Complete remission, PR: Partial Remission, NR: No Remission. ARB: Angiotensin II receptor blockers.

**Table B, web appendix. Univariable and multivariable Cox analysis**

	Complete remission (n=27)				Complete / Partial remission composite endpoint (n=65)			
	univariable		multivariable		univariable		multivariable	
	Hazard ratio (95% CI)	p-value	Hazard ratio (95% CI)	p-value	Hazard ratio (95% CI)	p-value	Hazard ratio (95% CI)	p-value
Age (y)	0.979 (0.954-1.005)	0.117			0.989 (0.973-1.005)	0.191		
Gender (1=F; 0=M)	3.714 (1.741-7.922)	0.001	2.496 (1.095-5.690)	0.03	3.13 (1.869-5.243)	<0.0001	1.591 (0.913-2.772)	0.101
Body weight (Kg)	0.964 (0.937-0.992)	0.011			0.975 (0.956-0.994)	0.012		
Map (mmHg)	0.962 (0.931-0.994)	0.022			0.988 (0.969-1.008)	0.241		
Serum creatinine (mg/dl) *	0.089 (0.021-0.379)	0.001	0.275 (0.062-1.221)	0.09	0.246 (0.120-0.504)	<0.0001	0.42 (0.196-0.897)	0.025
Serum albumin (g/dl)	1.876 (1.005-3.503)	0.048			2.362 (1.507-3.700)	<0.0001		
Total serum cholesterol (mg/dl)	0.996 (0.990-1.002)	0.158			0.996 (0.992-1.000)	0.047		
Serum tryglicerides (mg/dl) *	0.113 (0.047-0.277)	<0.0001			0.273 (0.166-0.447)	<0.0001		
Proteinuria (g/24h) *	0.252 (0.119-0.536)	<0.0001	0.365 (0.147-0.908)	0.03	0.153 (0.090-0.262)	<0.0001	0.19 (0.107-0.338)	<0.0001
First vs. second-line treatment	0.967 (0.407-2.297)	0.94			1.241 (0.720-2.138)	0.437		
Rituximab regimen (four-dose vs. B-cell driven)	0.706 (0.324-1.538)	0.38			0.66 (0.400-1.090)	0.105		
Duration of persistent proteinuria (mo) *	0.908 (0.634-1.302)	0.601			0.879 (0.700-1.005)	0.27		

\* log transformation of the covariate

## Serum Albumin



## Serum Cholesterol




Figure A, web appendix